Physician profile
Jonathan D Kaplan
NPI 1255327284
$19,609.13
in general payments reported to CMS, 2019-2025
50 companies · $4,139 in 2025
The $4,139 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,753 · 2020: $1,639 · 2021: $2,485 · 2022: $2,409 · 2023: $2,860 · 2024: $3,324 · 2025: $4,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,089.52 |
| Education | $233.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,379.31 | 2019-2025 | |
| Janssen Biotech, INC. | $2,307.29 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,693.39 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,539.89 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $684.42 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $658.03 | 2019-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $566.49 | 2019-2025 | Ocaliva |
| Daiichi Sankyo INC. | $565.86 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $549.62 | 2019-2025 | Rebyota, Clenpiq |
| Lilly USA, LLC | $466.80 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $459.31 | 2019-2024 | Dificid, Zinplava, Zerbaxa |
| Braintree Laboratories, INC. | $451.47 | 2019-2025 | Sutab, Suflave |
| Celltrion USA INC. | $430.15 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Pfizer INC. | $405.96 | 2019-2025 | |
| Cumberland Pharmaceuticals, INC. | $374.78 | 2019-2023 | Kristalose |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $373.31 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $342.69 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $308.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $258.23 | 2019-2020 | |
| Gilead Sciences, INC. | $234.18 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $228.92 | 2021-2023 | |
| Pharmacosmos Therapeutics INC. | $221.70 | 2023-2025 | Monoferric |
| Ironwood Pharmaceuticals, INC | $192.00 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $153.24 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $150.82 | 2025 | Wegovy |
| Vivus LLC | $148.41 | 2020-2025 | Pancreaze, Qsymia |
| Aimmune Therapeutics, INC. | $145.41 | 2024-2025 | Vowst, Zenpep |
| E.R. Squibb & Sons, L.L.C. | $139.70 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Redhill Biopharma INC. | $117.10 | 2020-2024 | Talicia, Aemcolo |
| Ucb, INC. | $113.60 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $108.49 | 2023-2024 | Idacio |
| Amgen INC. | $97.88 | 2021-2022 | |
| Shire North American Group INC | $84.96 | 2019 | |
| Genzyme Corporation | $80.72 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $58.15 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $50.49 | 2021-2022 | |
| Evoke Pharma, INC. | $47.18 | 2023 | Gimoti |
| Romark Laboratories, Lc | $40.62 | 2019 | |
| Lucid Diagnostics INC. | $32.97 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $26.71 | 2025 | Iqirvo |
| Shionogi INC | $26.05 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $24.58 | 2023 | Fna Fnb |
| Organon LLC | $24.06 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.57 | 2019 | |
| Genentech USA, INC. | $22.26 | 2021 | |
| Biocon Biologics INC | $21.68 | 2024 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.89 | 2023 | |
| Medtronic, INC. | $18.79 | 2023 | Interstim |
| Axonics, INC. | $15.63 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.